2d
MarketBeat on MSNGLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss TrendsThe supply shortage and high costs of GLP-1 weight loss drugs have created an opportunity for compounded GLP-1 treatments to ...
After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (NYSE: LLY) announced ...
As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...
Food companies are capitalizing on the GLP-1 trend, offering high-protein, portion-controlled meals. But are they meeting ...
“GLP-1 agonists appear to be less affected by this ... “Clinicians already balance a range of factors when deciding on the best treatment for an individual. This includes the person’s ...
From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...
Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA ...
“GLP-1 medications have changed the way doctors treat ... discuss these aspects with their patients and help to choose the best treatment option for them.” The findings were published online ...
Viewers of the Super Bowl may have seen an ad from one of the largest compounders in the United States, Hims & Hers, ...
However, GLP-1 agonists had more effect in younger, female participants. Which diabetes treatment works best for who? “Both SGLT2 inhibitors and GLP-1 agonists are excellent drug categories that have ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results